{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:50:44Z","timestamp":1761630644475},"reference-count":50,"publisher":"Frontiers Media SA","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":894,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transpl Int"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1111\/tri.12085","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T06:36:46Z","timestamp":1363847806000},"page":"527-534","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection"],"prefix":"10.3389","volume":"26","author":[{"given":"Christoph","family":"Logge","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery and Visceral Transplantation; University Medical Center Hamburg-Eppendorf; Hamburg; Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eik","family":"Vettorazzi","sequence":"additional","affiliation":[{"name":"Department of Biometry and Epidemiology; University Medical Center Hamburg-Eppendorf; Hamburg; Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery and Visceral Transplantation; University Medical Center Hamburg-Eppendorf; Hamburg; Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Nashan","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery and Visceral Transplantation; University Medical Center Hamburg-Eppendorf; Hamburg; Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Sterneck","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery and Visceral Transplantation; University Medical Center Hamburg-Eppendorf; Hamburg; Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2013,3,21]]},"reference":[{"issue":"Suppl. 10","key":"10.1111\/tri.12085-BIB0001|tri12085-cit-0001","first-page":"S286","article-title":"Chronic hepatitis C: an age wave of disease burden","volume":"11","author":"McHutchison","year":"2005","journal-title":"Am J Manag Care"},{"issue":"Suppl. 2","key":"10.1111\/tri.12085-BIB0002|tri12085-cit-0002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/lt.21646","article-title":"The natural history of recurrent hepatitis C and what influences this","volume":"14","author":"Gane","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12085-BIB0003|tri12085-cit-0003","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJM199603283341302","article-title":"Long-term outcome of hepatitis C infection after liver transplantation","volume":"334","author":"Gane","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12085-BIB0004|tri12085-cit-0004","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/jhep.2002.33993","article-title":"Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients","volume":"36","author":"Berenguer","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/tri.12085-BIB0005|tri12085-cit-0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00007890-200201150-00010","article-title":"Impact of the recurrence of HCV infection after liver transplantation on the longterm viability of the graft","volume":"73","author":"S\u00e1nchez-Fueyo","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/tri.12085-BIB0006|tri12085-cit-0006","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1440-1746.2005.03795.x","article-title":"Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy","volume":"20","author":"Toniutto","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/tri.12085-BIB0007|tri12085-cit-0007","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs. 24\u00a0weeks in HCV genotype 2 or 3","volume":"352","author":"Mangia","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12085-BIB0008|tri12085-cit-0008","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa066403","article-title":"Peginterferon alfa-2a and ribavirin for 16 or 24\u00a0weeks in HCV genotype 2 or 3","volume":"357","author":"Shiffman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12085-BIB0009|tri12085-cit-0009","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1517\/14656560903321521","article-title":"Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: \u20182b or not 2b (= 2a), that is the question","volume":"10","author":"Toyoda","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/tri.12085-BIB0010|tri12085-cit-0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-2007-971069","article-title":"Chronic HCV infections. A model disease for therapy, economics and social-medical aspects","volume":"69","author":"Rossol","year":"2007","journal-title":"Gesundheitswesen"},{"key":"10.1111\/tri.12085-BIB0011|tri12085-cit-0011","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"issue":"Suppl. 2","key":"10.1111\/tri.12085-BIB0012|tri12085-cit-0012","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1002\/lt.21624","article-title":"Hepatitis C therapy before and after liver transplantation","volume":"14","author":"Terrault","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12085-BIB0013|tri12085-cit-0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2036.2007.03364.x","article-title":"Review article: the treatment of hepatitis C virus recurrence after liver transplantation","volume":"26","author":"Arjal","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/tri.12085-BIB0014|tri12085-cit-0014","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0272989X9701700205","article-title":"Primer on medical decision analysis: part 5 - working with Markov processes","volume":"17","author":"Naimark","year":"1997","journal-title":"Med Decis Making"},{"key":"10.1111\/tri.12085-BIB0015|tri12085-cit-0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"10.1111\/tri.12085-BIB0016|tri12085-cit-0016","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"key":"10.1111\/tri.12085-BIB0017|tri12085-cit-0017","volume-title":"Cost-Effectiveness in Health and Medicine","year":"1996"},{"key":"10.1111\/tri.12085-BIB0018|tri12085-cit-0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"10.1111\/tri.12085-BIB0019|tri12085-cit-0019","first-page":"107","article-title":"Leitlinien zur gesundheits\u00f6konomischen Evaluation","volume":"9","author":"Greiner","year":"1999","journal-title":"Nomos: Baden-Baden"},{"key":"10.1111\/tri.12085-BIB0020|tri12085-cit-0020","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jhep.2006.12.017","article-title":"A randomited study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C","volume":"46","author":"Angelico","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12085-BIB0021|tri12085-cit-0021","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2003.12.015","article-title":"Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination","volume":"40","author":"Dumortier","year":"2004","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12085-BIB0022|tri12085-cit-0022","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12085-BIB0023|tri12085-cit-0023","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12085-BIB0024|tri12085-cit-0024","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1053\/jhep.2000.17924","article-title":"Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation","volume":"32","author":"Berenguer","year":"2000","journal-title":"Hepatology"},{"key":"10.1111\/tri.12085-BIB0025|tri12085-cit-0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0002-9610(01)00595-5","article-title":"Late mortality after orthotopic liver transplantation","volume":"181","author":"Rabkin","year":"2001","journal-title":"Am J Surg"},{"key":"10.1111\/tri.12085-BIB0026|tri12085-cit-0026","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.52.3.425","article-title":"Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"52","author":"Siebert","year":"2003","journal-title":"Gut"},{"key":"10.1111\/tri.12085-BIB0027|tri12085-cit-0027","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"Chong","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/tri.12085-BIB0028|tri12085-cit-0028","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0272989X08315240","article-title":"Health-state utilities in liver disease: a systematic review","volume":"28","author":"McLernon","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1111\/tri.12085-BIB0029|tri12085-cit-0029","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2011.12.031","article-title":"Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy","volume":"56","author":"Berenguer","year":"2012","journal-title":"J Hepatology"},{"key":"10.1111\/tri.12085-BIB0030|tri12085-cit-0030","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomised study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12085-BIB0031|tri12085-cit-0031","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/TP.0b013e3181bd783c","article-title":"Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome","volume":"88","author":"Selzner","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/tri.12085-BIB0032|tri12085-cit-0032","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/lt.21635","article-title":"Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis","volume":"14","author":"Roche","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12085-BIB0033|tri12085-cit-0033","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0272989X9801800312","article-title":"Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method","volume":"18","author":"Hunink","year":"1998","journal-title":"Med Decis Making"},{"key":"10.1111\/tri.12085-BIB0034|tri12085-cit-0034","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cld.2009.05.008","article-title":"Boceprevir, an NS3 protease inhibitor of HCV","volume":"13","author":"Berman","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1111\/tri.12085-BIB0035|tri12085-cit-0035","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12085-BIB0036|tri12085-cit-0036","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12085-BIB0037|tri12085-cit-0037","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12085-BIB0038|tri12085-cit-0038","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.290.2.228","article-title":"Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population","volume":"290","author":"Salomon","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/tri.12085-BIB0039|tri12085-cit-0039","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/003655201750313414","article-title":"Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden","volume":"36","author":"Sennf\u00e4lt","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/tri.12085-BIB0040|tri12085-cit-0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/gut.50.2.253","article-title":"Cost effectiveness of combination therapy for hepatitis C: a decision analytic model","volume":"50","author":"Stein","year":"2002","journal-title":"Gut"},{"key":"10.1111\/tri.12085-BIB0041|tri12085-cit-0041","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/hep.510300518","article-title":"Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C","volume":"30","author":"Younossi","year":"1999","journal-title":"Hepatology"},{"key":"10.1111\/tri.12085-BIB0042|tri12085-cit-0042","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/jlts.2002.32717","article-title":"Is it cost-effective to treat recurrent hepatitis C infection in othotopic liver transplantation patients?","volume":"8","author":"Saab","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12085-BIB0043|tri12085-cit-0043","first-page":"748","article-title":"Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model","volume":"16","author":"Saab","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12085-BIB0044|tri12085-cit-0044","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"Association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12085-BIB0045|tri12085-cit-0045","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jhep.2004.06.029","article-title":"Fibrosis progression after liver transplantation in patients with recurrent hepatitis C","volume":"41","author":"Neumann","year":"2004","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12085-BIB0046|tri12085-cit-0046","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/j.1600-6143.2006.01408.x","article-title":"The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C","volume":"6","author":"Foxton","year":"2000","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12085-BIB0047|tri12085-cit-0047","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/j.1572-0241.2002.05995.x","article-title":"Contribution of obesity to hepatitis C-related fibrosis progression","volume":"97","author":"Ortiz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/tri.12085-BIB0048|tri12085-cit-0048","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/lt.22271","article-title":"PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus","volume":"17","author":"Bzowej","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12085-BIB0049|tri12085-cit-0049","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/lt.21548","article-title":"Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection","volume":"14","author":"Kuo","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1111\/tri.12085-BIB0050|tri12085-cit-0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"J Hepatol"}],"container-title":["Transplant International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftri.12085","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tri.12085\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T18:39:57Z","timestamp":1641062397000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tri.12085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,21]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"URL":"https:\/\/doi.org\/10.1111\/tri.12085","relation":{},"ISSN":["0934-0874"],"issn-type":[{"value":"0934-0874","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3,21]]}}}